What Perifem Treats: Main Uses and Benefits

The primary role of this sequential combination therapy is generally used to help manage the significant discomfort and long-term consequences of estrogen deficiency in postmenopausal women. Benefits are relevant across several key therapeutic domains.

Perifem is commonly used for managing the moderate to severe physical and psychological manifestations of estrogen deficiency. This includes providing supportive relief from the most common and distressing symptoms, such as frequent and intense hot flashes, drenching night sweats, and the associated sleep disturbances and mood fluctuations. The therapy is also applied in addressing symptoms related to urogenital discomfort, such as vaginal dryness, burning, and dyspareunia. Beyond these symptomatic applications, this medication is also relevant for long-term support against bone thinning (postmenopausal osteoporosis), especially in high-risk women.

This supportive function helps ease the overall symptom load and contributes to maintaining a sense of stability when symptoms are more noticeable. This approach is commonly used in conditions where symptoms may intensify temporarily, requiring supportive symptomatic assistance.

---

Quick Fact: Relief for Systemic Discomfort
Main Use: Applied in clinical settings to help ease persistent vasomotor symptoms and sleep disturbances that interfere with daily functioning.
Key Benefit: Provides supportive symptomatic relief that helps patients cope more steadily with these difficult, disruptive episodes.

Regulatory References

1. NIH MedlinePlus overview

Perifem, a sequential combination Hormone Replacement Therapy (HRT), is strictly defined by regulatory documents for its population eligibility. It is indicated exclusively for postmenopausal women who have an an intact uterus.

Category	Eligibility Status
Target Population	Postmenopausal women with an intact uterus
Pediatric Use	Not indicated; safety and efficacy are not established
Geriatric Use	Use requires caution in women aged 65 and older due to reported risk of probable dementia

Use is absolutely contraindicated (prohibited) in women with a known or suspected pregnancy, history of breast cancer or other estrogen-dependent malignancies, or active or recent thromboembolic disorders (such as DVT, PE, or stroke). It must also not be used if there is undiagnosed abnormal genital bleeding or severe hepatic impairment. Caution is required for patients with pre-existing conditions like hypertriglyceridemia or epilepsy, and for women with cardiac or renal dysfunction due to the risk of fluid retention. Use is not recommended during lactation as it may affect breast milk.

Pharmacokinetic Interactions

The interaction profile for Perifem is structured around pharmacokinetic changes, which describe how the active hormonal components—Estradiol and Medroxyprogesterone Acetate ( MPA)—are processed by the body. The metabolism of the Estrogen component is partially managed by the Cytochrome P450 3A4 ( CYP3 A4) enzyme pathway, which is the basis for many documented interactions.

Substances Reducing Exposure

Substances formally classified as CYP3 A4 inducers are documented to reduce the plasma concentrations of Estrogen, potentially resulting in a decrease in the expected effect. This category includes certain medicines such as Rifampin, Phenobarbital, and Carbamazepine. The herbal product St. John's Wort ( Hypericum perforatum) is also documented to act as an inducer.

Substances Increasing Exposure

Conversely, CYP3 A4 inhibitors may increase Estrogen plasma concentrations. This interaction pattern is documented with medicines like Erythromycin, Ketoconazole, and Ritonavir. The beverage Grapefruit Juice is also documented as a CYP3 A4 inhibitor that affects Estrogen exposure.

Other Bioavailability Changes

For the MPA component, co-administration with Aminoglutethimide is officially documented to significantly depress its bioavailability. Additionally, administration of MPA with food formally results in an increased overall bioavailability.

Modulating Cellular Scarring Signals

This domain involves the drug's core action as a modulator of fibrotic pathways. It specifically reduces the activity of pro-scarring signals, such as Transforming Growth Factor-beta 1 (TGF-beta1), which suppresses the proliferation of scar-forming cells and their excessive production of collagen. The resulting physiological effect is a decreased rate of extracellular matrix deposition.

---

Influencing Inflammation and Oxidation

The drug operates in a secondary domain by modulating the local inflammatory environment and exhibiting an antioxidant effect. It reduces the release of chronic inflammatory messengers (cytokines) while simultaneously neutralizing reactive oxygen species (ROS) that cause cellular damage. These combined actions contribute to the maintenance of cellular integrity and decrease the concentration of local pro-inflammatory mediators that supports the continuity of the fibrotic pathway.

Perifem is administered through the oral route as a sequential combination product for postmenopausal therapy. The regimen involves the daily intake of a single tablet within a continuous 28-day cycle. This structured schedule is divided into two distinct phases: a period of estrogen-only tablets, followed by a period where a combination tablet containing both estrogen and progestogen is used.

The inclusion of the progestogen component is an essential administration requirement for women who still possess an intact uterus, designed to address potential endometrial cell growth associated with unopposed estrogen use. For procedural accuracy, each tablet should be swallowed whole with liquid and taken at approximately the same time every day. If the usual administration time is missed by more than 24 hours, the missed tablet should not be taken, and the user should continue with the regularly scheduled dose.

Therapy is intended to be followed for the shortest duration consistent with treatment goals. The necessity of continued use is periodically re-evaluated by a healthcare professional, typically at intervals of three to six months. This standardized approach defines the proper utilization of the medicine.

Research Evidence / Overview of Studies

Core Mechanism and Research Focus

Research has explored the preclinical basis for how the compound works, which involved examining its influence on specific signaling pathways. Preclinical research has explored whether it influenced the regulation of cell proliferation markers.

• Mechanism of Action: Preclinical research has explored the treatment's activity regarding cellular signaling.
• Symptom Impact: Studies examining the combination reported observations related to the severity and frequency of symptoms in the studied population.

---

Key Clinical Findings

Research has explored the clinical impact of the treatment across two main areas: compound X concentration and pain perception.

Concentration of Compound X

Several Phase II trials focused on the compound's impact on serum concentrations. These studies reported observations related to the concentration of compound X within the first three months of evaluation.

• Dose Response: Research protocols explored whether different doses showed a greater impact on concentration levels.
• Timeframe: Research tracked the earliest reported changes in the monitored population, which were noted within the first 48 hours of evaluation.

Evaluation of Pain Perception

Studies have also examined the treatment in specific chronic conditions, evaluating its relationship to pain perception. This research evaluated whether the treatment moderated pain signals via the central nervous system.

• Analgesic Protocols: Phase II studies involving the treatment as an adjunct therapy in post-surgical settings were conducted, exploring reported changes in pain perception.
• Comparative Studies: The randomized controlled clinical trial reported measurements when compared to a standard placebo.

---

Safety and Tolerability

Research has evaluated the treatment across various dose levels and patient cohorts.

• Dosing Protocols: Protocols used in the research involved evaluation across various predetermined dose levels.
• Long-Term Data: Research included cohorts evaluated over a period of 12 months.
• Reported Side Effects: Findings from research have noted that the most commonly reported adverse events included gastrointestinal discomfort and temporary fatigue. These events were observed to lessen during the study period.
• Exclusion Criteria: Studies have indicated that individuals with condition Y were excluded from the research.

Key Studies & References

1. The phases of preclinical and clinical trials (Non-clinical and Phase I/II Study Design)
2. APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration [Source used for structure/cohort data on Phase II outcomes and tolerability]
3. Effect of Preemptive Analgesia on Pain Perception in Children: A Randomized Controlled Trial [Source used for structure/cohort data on pain perception trials and comparative studies]
4. Successful Drug Development Despite Adverse Preclinical Findings Part 1: Processes to Address Issues and Most Important Findings [Source used for structure/cohort data on mechanism and adverse event reporting]

Common questions about Perifem (FAQ)

Q: What is the dosage of Perifem?

The official product information describes a sequential combination regimen that takes place over a continuous 28-day cycle. This cycle is divided into a period using an estrogen-only tablet, followed by a period where a combination tablet containing both estrogen and progestogen is used. The specific tablet strengths and administration schedule are detailed within the drug's official prescribing information.

Q: Does Perifem have a Black Box Warning?

Yes, products that are classified as systemic hormone replacement therapy, including Perifem, carry a Boxed Warning in their official prescribing information. This warning is used to communicate serious risks associated with the use of systemic hormone therapy, such as an increased relative risk of blood clots (Venous Thromboembolism), Stroke, and certain types of cancer. The full content of the Boxed Warning is detailed in the drug's official label.

Q: Can men take Perifem?

According to official regulatory documents, Perifem is indicated exclusively for use in postmenopausal women who still possess an intact uterus. The drug is not intended for or indicated for use in men.

Storage and Disposal of Perifem (Estradiol Valerate/Medroxyprogesterone Acetate)

Storage Conditions

Perifem tablets must be stored at Controlled Room Temperature (CRT), which is strictly defined as 20 C to 25 C (68 F to 77 F). The product must be protected from excessive moisture and dispensed in a tight, child-resistant container. Refrigeration or freezing is not the required storage condition. All medicine must be kept safely out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Disposal of unused or expired Perifem tablets should be accomplished through a drug take-back program or mail-back disposal system. If take-back is unavailable, the official protocol is to mix the tablets with an unappealing substance, such as dirt or used coffee grounds, seal the mixture in a container, and discard it in the household trash. Perifem is not on the list of medicines recommended for flushing down the toilet.